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Abstract
Introduction: Pregnant women exposed chronically to opioids smoked more cigarettes per day
(CPD) and had a higher nicotine metabolite ratio (NMR), 3-hydroxycotinine/cotinine, a biomarker
of nicotine metabolism and clearance, than those not receiving opioids. We examined CPD and
NMR in a group of pregnant smokers, a quarter of whom were receiving opioid agonist therapy
(OAT).
Aims and Methods: Pregnant smokers recruited to participate in a placebo-controlled trial of bupropion for smoking cessation provided a blood sample for measurement of NMR.
Results: Half (52.4%) of the 124 women with NMR data were African American. OAT-treated
women (n = 34, 27.4%; 27 receiving methadone and 7 buprenorphine) were more likely to be white
(79% vs. 30%, p < .001) and to have a lower mean PHQ-9 total score (2.91 [SD = 2.83] vs. 4.83
[SD = 3.82], p = .007). OAT-treated women reported smoking more CPD (9.50 [SD = 5.26] vs. 7.20
[SD = 3.65], p = .005) and had higher NMR (0.78 [SD = 0.36] vs. 0.56 [SD = 0.25], p = .001) than the
non-OAT-treated group. In a linear regression analysis adjusting for race, depression severity, and
CPD, NMR was greater in the OAT group (p = .025), among whom the daily methadone-equivalent
dosage correlated with NMR (Spearman’s ρ = 0.49, p = .003).
Conclusions: Consistent with the findings of Oncken et al. (2019), we found that OAT smokers
smoked more and had higher NMR than non-OAT smokers. As higher NMR is associated with a reduced likelihood of smoking cessation, the effects on NMR of both pregnancy and OAT could contribute to a lower smoking cessation rate in pregnant smokers receiving chronic opioid therapy.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Implications: We replicated the finding that the NMR is significantly greater among pregnant
smokers receiving OAT than those not receiving this treatment for opioid use disorder. Furthermore,
we found that the dosage of the OAT was significantly associated with the NMR level. These findings may contribute to a poorer response to smoking cessation treatment in pregnant women
treated with OAT, particularly those receiving high-dose therapy, and raise the question of whether
novel approaches are needed to treat smoking in this subgroup of pregnant smokers.

Introduction
In 2016, 9.4% of U.S. women reported smoking before becoming
pregnant, with rates decreasing during pregnancy.1 Nonetheless, cigarette smoking during pregnancy is estimated to contribute to 5.3%–
7.7% of preterm deliveries, 13.1%–19.0% of low-birth-weight
deliveries, 23.2%–33.6% of cases of sudden infant death syndrome,
and 5.0%–7.3% of preterm-related deaths.2 When treated with
FDA-approved medications for tobacco use, pregnant smokers show
lower rates of smoking cessation than nonpregnant women.3 This is
due, in part, to the induction of the enzymes CYP2A6 and UGT2B10
and a higher rate of nicotine metabolism, which begins by 12 weeks
of gestation and continues throughout pregnancy.4,5
The ratio of the nicotine metabolites 3′-hydroxycotinine (3HC)
to cotinine (nicotine metabolite ratio [NMR]) reflects the rate of
nicotine metabolism and clearance. The NMR is largely determined
by the activity of CYP2A6, encoded by the gene CYP2A6, and
other genetic and environmental influences.6,7 The NMR is highly
reproducible and independent of the time since the last cigarette.8
Importantly, slow metabolizers of nicotine have significantly higher
quit rates than faster metabolizers, both in the absence of pharmacotherapy and with nicotine replacement therapy and in smokers of
both European9 and African ancestry.10
Opioid use disorder (OUD) is also an important factor contributing to the effectiveness of smoking cessation efforts. For example,
methadone-maintained OUD patients have a smoking prevalence
that is about fourfold and sustained smoking cessation rates with
treatment half or less that of the general population.11 As in the
general population, opioid use in pregnancy has increased dramatically in recent years.12 Although opioid agonist therapy (OAT) is the
recommended treatment for OUD during pregnancy, chronic opioid
exposure appears to augment the effects of pregnancy on NMR.13
Thus, efforts to promote smoking cessation during pregnancy among
women receiving OAT may be less successful than among pregnant
smokers not receiving OAT. In the present study, we examined the
daily smoking rate and NMR in pregnant smokers differentiated by
the presence or absence of OAT.

Methods
Participants
Subjects (N = 129) were recruited to participate in a randomized,
placebo-controlled trial of bupropion for smoking cessation among
pregnant smokers (clinicaltrials.gov: NCT02188459). They were eligible to participate if they smoked at least 3 cigarettes per day (CPD)
for the preceding 7 days, wanted to quit smoking, were at 13–26
weeks of gestation, at least 18 years old, able to speak English, and
able to sign written informed consent and commit to completing the
study procedures. We excluded individuals with a current substance
use disorder other than nicotine and opioid use disorders, including
alcohol use disorder, multiple gestations other than twins, an unstable
psychiatric or medical problem, current use of psychotropic medication, a known congenital abnormality, a history of a seizure disorder,

current use of any other smoking cessation medication, anorexia or
bulimia, or use of other tobacco products. The study was approved
by institutional review boards at all participating centers and was
conducted from October 30, 2014 through January 22, 2020.
The current analyses include 124 pregnant smokers with biomarker data at baseline. We excluded five participants whose NMR
could not be calculated, either because a blood sample could not be
obtained (n = 1) or their cotinine and 3HC levels were below the
level of quantification (n = 4).

Procedure and Measures
Baseline demographic and clinical variables included age, race,
marital status, gestational age (in weeks), and depression symptom
severity (measured using the nine-item Patient Health Questionnaire
or PHQ-914). We obtained a medication history and OAT was identified through self-report and medical record review. At baseline,
the average number of cigarettes smoked per day in the past 7 days
was assessed by self-report, and the Fagerström Test for Cigarette
Dependence (FTCD) was administered.15

Analytic Chemistry
Serum samples were assayed for the concentration of nicotine,
cotinine, and trans-3HC by Liquid Chromatography with tandem
mass spectrometry as previously described8 with limits of quantification of 1.0 ng/mL whole blood for each compound. We excluded
individuals with cotinine less than 10 ng/mL, which is suggestive
of non-daily smoking16 and yields unstable NMR measurements because cotinine is not at a steady state.

Data Analysis
NMR was calculated as the ratio of 3HC/cotinine. In bivariate analyses, we tested differences in baseline characteristics by OAT status
using Wilcoxon tests for continuous variables and chi-square tests
for categorical variables. The distribution of NMR showed low
levels of skewness in both the OAT (skew = 0.21) and non-OAT
(skew = 0.24) groups, with no outliers, so we analyzed the raw
NMR score. We conducted multivariable linear regression to determine the associations between NMR and OAT status, with CPD,
PHQ-9 total, and race included as covariates, as they differed significantly by OAT status. For the regression analysis, we report the unstandardized regression coefficients, corresponding to the difference
in NMR mean between the OAT and non-OAT groups, adjusting
for the covariates. Because the distribution of OAT users differed by
race, in a secondary regression analysis, we examined the interaction
of race with OAT status on NMR.
Additionally, within the OAT group, we examined the associations between OAT daily dose and NMR using the daily dose
reported by participants (in milligrams). To establish equivalence
between dosing of methadone and buprenorphine, we multiplied
the buprenorphine daily doses by 5.17 To accommodate an outlier
on daily dose in the methadone group, we used Spearman rank
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Table 1. Pretreatment Demographic and Clinical Variables by Opioid Agonist Therapy (OAT) Status (N = 124)
OAT status

Age in years, mean (SD)
Race, n (%)
AA/black
EA/white
Other
Marital status, n (%)
Never married
Ever married
Gestational age in weeks, mean (SD)
PHQ-9 total score, mean (SD)
Cigarettes/day, mean (SD)
FTCD total score, mean (SD)
Serum cotinine (ng/mL), mean (SD)
Serum 3HC (ng/mL), mean (SD)
Nicotine metabolite ratio, mean (SD)

Non-OAT

OAT

pa

28.0 (4.6)

29.9 (5.3)

.087
<.0001
—
—
—
.73
—
—
.78
.007
.005
.36
.87
.074
.001

58 (64%)
27 (30%)
5 (6%)

7 (21%)
27 (79%)
0 (0%)

56 (62%)
34 (38%)
21.1 (3.9)
4.8 (3.8)
7.2 (3.6)
3.7 (1.8)
111.1 (70.9)
57.5 (44.2)
0.6 (0.3)

20 (59%)
14 (41%)
20.6 (4.6)
2.9 (2.8)
9.5 (5.3)
4.1 (2.0)
105.2 (61.7)
73.6 (50.4)
0.8 (0.4)

SD = standard deviation; AA = African American; EA = European American; FTCD = Fagerström Test for Cigarette Dependence; 3HC = 3-hydroxycotinine;
PHQ-9 = Patient Health Questionnaire-9. Numbers in bold are statistically significant.
a
p-values calculated using F-test for continuous variables and chi-square statistic for categorical variables.

correlations to summarize the association between NMR and daily
dose level within each group, with a robust regression method (using
a bisquare weight function) to test for main effects of daily dose and
interactions with OAT type.
We performed all analyses using SAS/STAT software, version 9.4
(SAS Institute Inc., Cary, NC).

Results
Table 1 shows the baseline demographic and clinical characteristics of
the 124 pregnant smokers included in the analyses comparing the OAT
and non-OAT groups. The groups were similar on mean age (29.91
[SD = 5.29] and 27.96 [SD = 4.63] years in the OAT and non-OAT
groups, respectively) and the likelihood of ever having married (41%
vs. 38%, respectively). However, the racial composition of the groups
differed significantly, with the OAT group predominantly (79%) of
European ancestry and the non-OAT group predominantly (64%) of
African ancestry. The non-OAT group had a higher mean PHQ-9 total
score (4.83 [SD = 3.82]) than the OAT group (2.91 [SD = 2.83]). The
mean number of CPD was significantly higher in the OAT group (9.50
[SD = 5.26]) than the non-OAT group (7.20 [SD = 3.65]), although
the FTCD total score was not (4.15 [SD = 1.99] in the OAT group
and 3.71 [SD = 1.80] in the non-OAT group). The gestational age
did not differ by group, which obviated controlling for this potential
effect on NMR.5 Most patients in the OAT group were being treated
with methadone (n = 27 or 79.4%; mean daily dosage = 91.0 mg
[SD = 62.6]) with the remainder receiving buprenorphine (n = 7 or
20.6%; mean daily dosage = 14.3 mg [SD = 3.2]). One participant reported a confirmed daily methadone dose of 360 mg; for the other 26
participants, the mean daily dose was 80.62 mg (SD = 32.70).

Nicotine Metabolite Concentrations and Ratio
Blood cotinine concentration did not differ by OAT status
(105.16 ng [SD = 61.70] and 111.13 ng [SD = 70.89] in the OAT
and non-OAT groups, respectively), with a nonsignificant trend
(p = .074) for a greater concentration of 3HC in the OAT group
(73.62 ng/mL [SD = 50.39]) than the non-OAT group (57.54 ng/
mL [SD = 44.18]). The mean NMR was significantly greater in

Table 2. Multivariable Linear Regression Model of Nicotine
Metabolite Ratio as a Function of Opioid Agonist Therapy Status,
Depression Severity, Race, and Smoking Intensity (N = 124)a

Opioid agonist therapy
Cigarettes per day (CPD)
PHQ-9 score
Race/ethnicity (vs. white)
African American
Other/Refused

β coefficientb

SE

p

0.14
−0.0006
−0.006

0.06
0.006
0.007

.025
.920
.373

−0.15
−0.02

0.05
0.13

.008
.859

SE = standard error.
a
Predictors: opioid agonist therapy and CPD; covariates: Patient Health
Questionnaire-9 (PHQ-9) and race.
b
We report the unstandardized regression coefficient.

the OAT group (0.78 [SD = 0.25]) than the non-OAT group (0.56
[SD = 0.25]), though within the OAT group, the mean NMR did not
differ between methadone-treated women (0.78 [SD = 0.40]) and the
buprenorphine-treated women (0.76 [SD = 0.12], p = .98).

Predictors of NMR
The results of the linear regression model of NMR adjusted for race,
PHQ-9 score, and CPD are presented in Table 2. The OAT group
had a higher NMR than the non-OAT group (b = 0.14, SE = 0.06,
p = .025), with African American (AA) women having a lower
NMR than European American (EA) women (b = −0.15, SE = 0.05,
p = .008). We conducted a secondary analysis that was restricted to
the 65 AAs and 54 EAs (which exclude five individuals of “other”
race), which yielded results very similar to those in the full sample:
the expected NMR value among the OAT is 0.15 (SE = 0.06) larger
than in OAT nonusers (p = .016). Within this reduced sample of 118,
there are 7 AAs (10.8%) and 27 EAs (50.0%) who were receiving
OAT, a distribution within populations that yields lower power than
a more even distribution would. An analysis of the interaction of
race by OAT was not significant: χ21 = 0.59, p = .44. Within AAs,
there is a small, nonsignificant effect: the expected NMR value
among OAT users is 0.08 (SE = 0.11) larger than in OAT nonusers
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(p = .47). Within EAs, the expected NMR value among OAT users is
0.18 (SE = 0.08, p = .015) larger than in OAT nonusers, results that
were similar to those in the full sample.
Neither CPD nor PHQ-9 score was associated with NMR.
Although changes in NMR have been observed across pregnancy,5
we tested women at approximately the same gestational age.
Among women receiving OAT (n = 34), a higher OAT dose was
associated with higher NMR levels (Spearman’s ρ = 0.49, p = .003).
The associations were of a similar magnitude within the methadoneonly (n = 27, ρ = 0.50, p = .05) and the buprenorphine-only (n = 7,
ρ = 0.45, p = .31) subgroups. In the main-effect robust regression
model, there was a significant positive association (β = 0.002,
SE = 0.001, p = .044) between daily OAT dose and NMR, but no
interaction of dose × OAT subgroup (p = .95).

Discussion
After controlling for relevant covariates, we found that the use of
OAT was associated with higher NMR among pregnant smokers.
Specifically, although cotinine levels were similar among smokers
irrespective of OAT, 3HC levels were marginally higher and NMR
was significantly higher among OAT smokers, findings that are
consistent with those of Oncken et al.13 In contrast to the prior
report, however, in which the NMR value was nominally greater
among women treated with methadone (56% of the sample; median
NMR = 0.63) than among those receiving buprenorphine (32% of
the sample; median NMR = 0.55), the two OAT medication groups
in our sample were nearly identical on NMR (methadone: 79.4%
of the sample; NMR = 0.78; buprenorphine 21.6%; NMR = 0.76).
We also found a moderate (ρ = 0.49), but significant, correlation
between the dosage of OAT and NMR, consistent with a pharmacological effect of OAT on NMR.
We found a nominally larger effect of OAT on NMR in EAs than
AAs. However, because of the small number of AAs who were receiving OAT (n = 7), we cannot draw a conclusion as to whether race
affects OAT’s impact to increase NMR during pregnancy. Future
studies in larger samples of AAs who are receiving OAT are needed
to evaluate the racial difference.
The prevalence and persistence of cigarette smoking in individuals with OUD far exceed that of the general U.S. adult population18
and the severity of nicotine dependence is significantly greater than
that among smokers without OUD.19 As reviewed above, a more
rapid nicotine metabolism, reflected by a higher NMR, is associated with a lower likelihood of smoking cessation. Thus, in addition
to the increase in NMR associated with pregnancy, chronic opioid
exposure also appears to increase NMR, and thus likely increases
nicotine metabolism. These may jointly contribute to the poorer response to smoking cessation treatment seen among pregnant women
with OUD.
The mechanism by which OAT increases the NMR during pregnancy remains to be determined. It could be via induced CYP2A6, but
opioids also compete in a dose-dependent manner for 5′-diphosphoglucuronosyltransferase (UGT) enzymes,20 which metabolize 3HC to
3HC glucuronide for excretion. Chronic opioid exposure is associated with lower 3HC metabolism, which increases NMR, an effect
that is consistent with the correlation observed here between OAT
dose and NMR.
Oncken et al.13 found a significant association of opioid exposure
and NMR only for methadone. In our sample, the NMR values for
the methadone- and buprenorphine-treated groups were similar.

Given the small number of buprenorphine-treated women in both
studies, further research on the effects of chronic opioid exposure on
NMR in pregnant smokers is warranted in samples large enough to
compare the effects of different opioids.
We found a moderate correlation between OAT dosage and
NMR, which was comparable in magnitude in the methadone and
buprenorphine groups. This contrasts with a study of nonpregnant
smokers maintained on buprenorphine, in which there was no effect of the drug’s dosage on NMR.21 Our study was limited by the
small number of smokers receiving OAT. Furthermore, although we
controlled for a variety of potential confounders, we did not have
information on whether the participants smoked menthol cigarettes,
which can affect nicotine metabolism; Oncken et al.13 found no such
effect of menthol cigarettes. Further research is needed to determine
whether a dose–response relationship that appears to exist for OAT
differs with the specific maintenance medication and the impact of
menthol cigarettes on this relationship.
In summary, we replicated the reported finding that pregnant
smokers receiving chronic opioid therapy have a higher NMR than
pregnant smokers not receiving opioids.13 The moderate correlation
that we observed between the dosage of OAT and NMR is consistent
with a pharmacokinetic interaction between nicotine and chronic
opioid therapy. Further research is needed to replicate these findings in a larger sample of pregnant smokers receiving OAT, so as to
ascertain whether there are different effects among opioid drugs, to
identify other factors that potentially affect NMR, and to elucidate
the mechanisms by which these effects occur.
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A Contributorship Form detailing each author’s specific involvement with this
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